PriceTargets.com logo

NASDAQ:BOLD - Audentes Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$59.97 As of 01/15/2020 01:00 AM ET
+0.30 (1.20%)
Get New Audentes Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BOLD

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Audentes Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $59.97.

This chart shows the closing price for BOLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Audentes Therapeutics. This rating has held steady since December 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 12 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/20/2020Chardan CapitalReiterated RatingHoldLow
12/16/2019MizuhoReiterated RatingHold$60.00Low
12/5/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$60.00Low
12/4/2019Chardan CapitalReiterated RatingBuy ➝ Neutral$60.00Low
12/4/2019SVB LeerinkDowngradeOutperform ➝ Hold$60.00Low
12/3/2019Wells Fargo & CompanyLower Price TargetOutperform$20.00 ➝ $19.00N/A
12/3/2019Raymond JamesDowngradeOutperform ➝ Market PerformN/A
12/3/2019HC WainwrightDowngradeBuy ➝ Neutral$60.00N/A
12/3/2019MizuhoDowngradeBuy ➝ NeutralN/A
12/3/2019WedbushDowngradeOutperform ➝ Neutral$60.00N/A
12/3/2019CitigroupUpgradeSell ➝ Neutral$30.00 ➝ $60.00N/A
12/3/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$47.00 ➝ $60.00N/A
12/3/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$55.00 ➝ $60.00N/A
12/3/2019Robert W. BairdUpgradeUnderperform ➝ NeutralN/A
12/3/2019GuggenheimDowngradeBuy ➝ NeutralN/A
11/27/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
11/22/2019Piper Jaffray CompaniesReiterated RatingBuy$55.00Low
11/19/2019Evercore ISIUpgradeIn-Line ➝ Outperform$40.00High
11/11/2019Evercore ISIReiterated RatingHold$34.00High
11/8/2019HC WainwrightReiterated RatingBuy$48.00High
10/6/2019Chardan CapitalReiterated RatingBuy$50.00Low
10/2/2019Robert W. BairdInitiated CoverageUnderperform$10.00 ➝ $10.00Medium
9/3/2019Chardan CapitalBoost Price TargetBuy$40.00 ➝ $50.00High
8/7/2019MizuhoReiterated RatingBuy$45.00High
8/7/2019William BlairReiterated RatingHoldHigh
5/8/2019HC WainwrightSet Price TargetBuy$48.00Low
5/8/2019BMO Capital MarketsSet Price TargetBuy$47.00Low
4/26/2019HC WainwrightBoost Price TargetBuy ➝ Buy$44.00 ➝ $48.00Low
4/26/2019CitigroupDowngradeNeutral ➝ Sell$28.00 ➝ $32.00Low
4/17/2019SVB LeerinkBoost Price TargetOutperform$37.00 ➝ $48.00High
4/9/2019WedbushBoost Price TargetOutperform$52.00 ➝ $57.00Medium
4/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Positive$45.00 ➝ $55.00Low
3/18/2019HC WainwrightReiterated RatingBuy$33.00 ➝ $44.00Low
2/27/2019William BlairReiterated RatingHoldHigh
2/25/2019Chardan CapitalUpgradeNeutral ➝ Buy$35.00 ➝ $40.00High
2/1/2019MizuhoReiterated RatingBuy$45.00High
1/31/2019CowenReiterated RatingBuyMedium
1/31/2019William BlairReiterated RatingHoldLow
1/11/2019HC WainwrightReiterated RatingBuy$33.00Medium
1/11/2019GuggenheimUpgradeNeutral ➝ Buy$35.00High
12/10/2018CitigroupLower Price TargetNeutral ➝ Neutral$40.00 ➝ $28.00Low
12/2/2018JPMorgan Chase & Co.Initiated CoverageOverweight$23.91High
11/26/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$35.00High
11/7/2018Raymond JamesReiterated RatingHoldHigh
11/7/2018B. RileyBoost Price TargetSell$20.00 ➝ $21.00High
11/7/2018HC WainwrightSet Price TargetBuy$33.00High
11/7/2018MizuhoReiterated RatingBuy$45.00High
11/6/2018William BlairDowngradeOutperform ➝ Market PerformHigh
10/14/2018HC WainwrightSet Price TargetBuy$33.00Low
10/9/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
10/8/2018HC WainwrightSet Price TargetBuy$33.00 ➝ $29.00Low
10/8/2018WedbushLower Price TargetOutperform ➝ Outperform$52.00 ➝ $49.00Low
10/5/2018Raymond JamesReiterated RatingHoldLow
10/5/2018William BlairReiterated RatingBuyHigh
10/3/2018MizuhoReiterated RatingBuy$45.00Medium
9/25/2018HC WainwrightSet Price TargetBuy$40.00Low
9/7/2018CowenInitiated CoverageSell ➝ Sell$20.00High
9/7/2018B. RileyInitiated CoverageSell ➝ Sell$20.00High
8/22/2018HC WainwrightSet Price TargetBuy$40.00High
8/22/2018MizuhoReiterated RatingBuy$45.00Medium
8/20/2018CitigroupInitiated CoverageNeutral$40.00Low
8/8/2018WedbushReiterated RatingOutperform$49.00High
8/8/2018Raymond JamesReiterated RatingHoldHigh
8/8/2018HC WainwrightSet Price TargetBuy$40.00High
8/8/2018MizuhoUpgradeNeutral ➝ Buy$26.00High
8/7/2018William BlairReiterated RatingBuyHigh
6/25/2018Chardan CapitalInitiated CoverageNeutral$35.00Medium
5/21/2018MizuhoReiterated RatingNeutral ➝ Hold$38.00Low
5/17/2018Raymond JamesReiterated RatingHoldHigh
5/17/2018HC WainwrightSet Price TargetBuy$40.00High
5/17/2018William BlairReiterated RatingBuyHigh
5/11/2018Raymond JamesReiterated RatingHoldMedium
5/10/2018WedbushBoost Price TargetOutperform$49.00 ➝ $56.00High
5/10/2018HC WainwrightSet Price TargetBuy$37.00High
5/2/2018HC WainwrightSet Price TargetBuy$37.00Low
3/9/2018CowenReiterated RatingBuyLow
3/9/2018WedbushReiterated RatingOutperform$56.00High
3/9/2018HC WainwrightSet Price TargetBuy$37.00Medium
3/9/2018William BlairReiterated RatingBuyMedium
2/12/2018MizuhoInitiated CoverageNeutral ➝ Neutral$26.00Medium
2/7/2018HC WainwrightReiterated RatingBuy$37.00High
1/11/2018HC WainwrightSet Price TargetBuy$37.00High
1/5/2018BMO Capital MarketsSet Price TargetBuy$44.00High
1/5/2018William BlairReiterated RatingBuyHigh
1/4/2018Raymond JamesReiterated RatingHoldHigh
1/4/2018WedbushBoost Price TargetOutperform$56.00High
1/4/2018HC WainwrightSet Price TargetBuy$37.00High
12/20/2017HC WainwrightInitiated CoverageBuy ➝ Buy$37.00Low
12/5/2017BMO Capital MarketsInitiated CoverageOutperform$35.00Low
11/15/2017SVB LeerinkReiterated RatingOutperform$22.00 ➝ $29.00N/A
10/17/2017William BlairInitiated CoverageOutperform$35.00N/A
10/12/2017Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformN/A
9/22/2017Bank of AmericaReiterated RatingBuy$23.00 ➝ $33.00Low
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$23.00Low
5/15/2017WedbushReiterated RatingOurperform$20.00Low
5/1/2017SVB LeerinkInitiated CoverageOutperform$22.00Low
(Data available from 1/17/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Audentes Therapeutics logo
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $59.97
Low: $59.97
High: $59.97

50 Day Range

MA: $59.97
Low: $59.97
High: $59.97

52 Week Range

Now: $59.97
Low: $22.00
High: $60.00

Volume

N/A

Average Volume

1,504,389 shs

Market Capitalization

$2.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Audentes Therapeutics?

The following Wall Street sell-side analysts have issued reports on Audentes Therapeutics in the last twelve months:
View the latest analyst ratings for BOLD.

What is the current price target for Audentes Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Audentes Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Audentes Therapeutics in the next year.
View the latest price targets for BOLD.

What is the current consensus analyst rating for Audentes Therapeutics?

Audentes Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BOLD.

What other companies compete with Audentes Therapeutics?

Other companies that are similar to Audentes Therapeutics include QIAGEN, Repligen, Ginkgo Bioworks, Novavax, Neurocrine Biosciences, Exelixis, CRISPR Therapeutics, Vir Biotechnology, Halozyme Therapeutics, Beam Therapeutics, Denali Therapeutics, Fate Therapeutics, Abcam, Ablynx and Kodiak Sciences.

How do I contact Audentes Therapeutics' investor relations team?

Audentes Therapeutics' physical mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company's listed phone number is 415-818-1001 and its investor relations email address is [email protected] The official website for Audentes Therapeutics is www.audentestx.com.